November 29, 1999 |
Of all the questions we get about calcium, most come from women in their 40s and 50s who are rightfully worried about getting enough calcium to ward off osteoporosis later in life. But nobody can afford to skimp on calcium. Not women, not men and especially not children. Osteoporosis is a very expensive problem not just for the individuals who develop it, but for society at large.
December 6, 2004 |
Dentists may be able to help screen women for osteoporosis by looking at X-rays that they are taking anyway. Panoramic dental X-rays, which show the whole jaw, can also show the beginnings of low skeletal bone mineral density -- the first step toward osteoporosis, Japanese researchers have reported. Dr. Akira Taguchi of Hiroshima University Hospital in Japan and colleagues studied 316 women past menopause who had no symptoms of osteoporosis but who got dental X-rays.
December 12, 2001 |
Almost 20 million American women, or nearly half of those beyond menopause, have thinning bones and don't know it, one of the largest osteoporosis studies to date suggests. The study was funded by Merck & Co., maker of an osteoporosis drug. Using a relatively inexpensive imaging technique on 200,160 healthy women 50 and older, researchers found full-fledged osteoporosis in 7% and low bone density in an additional 40%. The women were then followed for a year to see how many broke bones.
November 18, 1995 |
A slow-release sodium fluoride compound, supplemented with calcium, was recommended for approval as a new drug for osteoporosis by a Food and Drug Administration advisory committee on Friday. The recommendation by the FDA endocrinological and metabolic drugs advisory committee is not binding on the agency, but such recommendations generally are followed. If approved, the drug would be marketed by Mission Pharmacal, a manufacturer based in San Antonio.
May 18, 2002 |
Celltech Group will work with Amgen Inc. on treatments for osteoporosis, a loss of bone density that can lead to fractures in elderly patients. Amgen gets marketing rights to Celltech drugs that target a protein linked to the illness, said Peter Allen, Celltech's finance director. Celltech will pay some costs until the end of Phase II tests and may opt to get some European rights. Shares of Celltech, Britain's largest biotechnology company, rose 55 cents to $16.85 on the NYSE.
December 3, 1999 |
A family of drugs already widely used to reduce cholesterol may provide the first effective treatment for osteoporosis, the bone-thinning disease that affects an estimated 28 million Americans. Unlike existing treatments, which merely slow or delay bone thinning, the drugs, called statins, actually increase bone density, Texas researchers report in today's Science.
CALIFORNIA | LOCAL
March 6, 1989 |
Daughters of women with osteoporosis appear to be at increased risk of developing the bone-thinning disease, Australian researchers reported last week. Dr. Ego Seeman and his colleagues at the Austin Hospital in Melbourne compared 32 women whose mothers had osteoporosis to 22 women whose mothers did not have the disease, which affects roughly 20 million Americans.
CALIFORNIA | LOCAL
October 3, 1996 |
Alendronate, a drug designed to build stronger bones in people prone to osteoporosis, can corrode the tube leading to the stomach if it is taken improperly, according to a study in the New England Journal of Medicine. A group led by Dr. Piet C. de Groen of the Mayo Clinic in Rochester, Minn., found three serious cases in which alendronate, trade named Fosamax, had apparently become lodged in the esophagus and had corroded its lining.
November 11, 2002 |
It's a familiar complaint: Men receive better medical care than women. Research has shown, for instance, that male heart attack victims are given more aggressive therapy than female heart patients. The problem has been blamed on bias -- doctors tend to think of heart attacks as a predominantly male problem. But a new study suggests that men may also be undertreated for conditions associated primarily with women.
CALIFORNIA | LOCAL
September 12, 1996 |
Fosamax, the first drug developed in 20 years to treat osteoporosis, also prevents the bone-thinning disease, according to a report presented Wednesday at a meeting of the American Society for Bone and Mineral Research. The two-year study, led by Dr. Michael McClung of the Oregon Osteoporosis Center in Portland, involved 1,609 women ages 45 to 59 who had been through menopause but had not suffered any fractures. The results showed that women taking Fosamax had a 3.